Unmet needs in ovarian cancer: Dividing histologic subtypes to exploit novel targets and pathways

Current Cancer Drug Targets

Volumn 13, Issue 6, 2013, Pages 698-707

  Galic, Vijaya ^a   Coleman, Robert L ^b   Herzog, Thomas J ^a  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

5 bisphosphate 3 kinase; Adenocarcinoma clear cell; Adenocarcinoma endometrioid; Adenocarcinoma mucinous; Breast cancer 1; Catalytic subunit alpha (PI3KCA); Cystadenocarcinoma serous; Early onset (BRCA1) and breast cancer 2; Early onset (BRCA2); Ovarian cancer; Phosphatidylinositol 4; Poly (ADP ribose) polymerase 1 (PARP1); Tp53

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; B RAF KINASE; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CAPECITABINE PLUS OXALIPLATIN; CARBOPLATIN; DOXORUBICIN; EP 100; EVEROLIMUS; FULVESTRANT; GEMCITABINE; INIPARIB; LETROZOLE; LEUPRORELIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 4, 5 BISPHOSPHATE 3 KINASE; PROTEIN P53; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; THALIDOMIDE; TREOSULFAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; XL 147; ZOPTARELIN DOXORUBICIN;

ABSENCE OF SIDE EFFECTS; CANCER PROGNOSIS; CLEAR CELL CARCINOMA; DEATH; DNA DAMAGE; DRUG MEGADOSE; FANCONI ANEMIA; FATIGUE; GENE MUTATION; HISTOLOGY; HUMAN; NAUSEA; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; UTERUS CANCER; VOMITING;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; MUTANT PROTEINS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; OVARY; PROGNOSIS; SIGNAL TRANSDUCTION;

EID: 84888093860     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096113139990002     Document Type: Review

References (86)

1. American Cancer Society. Cancer Facts & Figures, 2013; American Cancer Society: Atlanta, GA, 2013.
2. ] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™. Ovarian Cancer. Including Fallopian Tube Cancer and Primary Peritoneal Cancer. V.1.2013. http://www.nccn.org/professionals/physician_gls/PDF/ovarian.pdf (Accessed March 25, 2013).
3. Bast, R. C. Jr.; Hennessy, B.; Mills, G. B. The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer 2009, 9 (6), 415-428.
4. Campbell, I. G.; Russell, S. E.; Choong, D. Y.; Montgomery, K. G.; Ciavarella, M. L.; Hooi, C. S.; Cristiano, B. E.; Pearson, R. B.; Phillips, W. A. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004, 64 (21), 7678-7681.
5. Jones, S.; Wang, T. L.; Shih, I.; Mao, T. L.; Nakayama, K.; Roden, R.; Glas, R.; Slamon, D.; Diaz, L. A. Jr.; Vogelstein, B.; Kinzler, K. W.; Velculescu, V. E.; Papadopoulos, N. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010, 330 (6001), 228-231.
6. Wiegand, K. C.; Shah, S. P.; Al-Agha, O. M.; Zhao, Y.; Tse, K.; Zeng, T.; Senz, J.; McConechy, M. K.; Anglesio, M. S.; Kalloger, S. E.; Yang, W.; Heravi-Moussavi, A.; Giuliany, R.; Chow, C.; Fee, J.; Zayed, A.; Prentice, L.; Melnyk, N.; Turashvili, G.; Delaney, A. D.; Madore, J.; Yip, S.; McPherson, A. W.; Ha, G.; Bell, L.; Fereday, S.; Tam, A.; Galletta, L.; Tonin, P. N.; Provencher, D.; Miller, D.; Jones, S. J.; Moore, R. A.; Morin, G. B.; Oloumi, A.; Boyd, N.; Aparicio, S. A.; Shih, I.; Mes-Masson, A. M.; Bowtell, D. D.; Hirst, M.; Gilks, B.; Marra, M. A.; Huntsman, D. G. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 2010, 363 (16), 1532-1543.
7. Willner, J.; Wurz, K.; Allison, K. H.; Galic, V.; Garcia, R. L.; Goff, B. A.; Swisher, E. M. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum. Pathol. 2007, 38 (4), 607-613.
8. Winter, W. E.; Maxwell, G. L.; Tian, C.; Carlson, J. W.; Ozols, R. F.; Rose, P. G.; Markman, M.; Armstrong, D. K.; Muggia, F.; McGuire, W. P. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 2007, 25 (24), 3621-3627.
9. Gershenson, D. M.; Sun, C. C.; Bodurka, D.; Coleman, R. L.; Lu, K. H.; Sood, A. K.; Deavers, M.; Malpica, A. L.; Kavanagh, J. J. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol. Oncol. 2009, 114 (1), 48-52.
10. Zaino, R. J.; Brady, M. F.; Lele, S. M.; Michael, H.; Greer, B.; Bookman, M. A. Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer 2011, 117 (3), 554-562.
11. Kurman, R. J.; Shih, I. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int. J. Gynecol. Pathol. 2008, 27 (2), 151-160.
12. Kobel, M.; Huntsman, D.; Gilks, C. B. Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev. Mol. Med. 2008, 10, e22.
13. Gilks, C. B.; Prat, J. Ovarian carcinoma pathology and genetics: recent advances. Hum. Pathol. 2009, 40 (9), 1213-1223.
14. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474 (7353), 609-615.
15. Press, J. Z.; De, L. A.; Boyd, N.; Young, S.; Troussard, A.; Ridge, Y.; Kaurah, P.; Kalloger, S. E.; Blood, K. A.; Smith, M.; Spellman, P. T.; Wang, Y.; Miller, D. M.; Horsman, D.; Faham, M.; Gilks, C. B.; Gray, J.; Huntsman, D. G. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008, 8, 17.
16. du Bois, A.; Luck, H. J.; Meier, W.; Adams, H. P.; Mobus, V.; Costa, S.; Bauknecht, T.; Richter, B.; Warm, M.; Schroder, W.; Olbricht, S.; Nitz, U.; Jackisch, C.; Emons, G.; Wagner, U.; Kuhn, W.; Pfisterer, J. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl.Cancer Inst. 2003, 95 (17), 1320-1329.
17. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002, 360 (9332), 505-515.
18. Norquist, B.; Wurz, K. A.; Pennil, C. C.; Garcia, R.; Gross, J.; Sakai, W.; Karlan, B. Y.; Taniguchi, T.; Swisher, E. M. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 2011, 29 (22), 3008-3015.
19. Sakai, W.; Swisher, E. M.; Karlan, B. Y.; Agarwal, M. K.; Higgins, J.; Friedman, C.; Villegas, E.; Jacquemont, C.; Farrugia, D. J.; Couch, F. J.; Urban, N.; Taniguchi, T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008, 451 (7182), 1116-1120.
20. Gilks, C. B. Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. J. Oncol. 2010, 2010, 740968.
21. Gershenson, D. M.; Sun, C. C.; Lu, K. H.; Coleman, R. L.; Sood, A. K.; Malpica, A.; Deavers, M. T.; Silva, E. G.; Bodurka, D. C. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet. Gynecol. 2006, 108 (2), 361-368.
22. Crispens, M. A.; Bodurka, D.; Deavers, M.; Lu, K.; Silva, E. G.; Gershenson, D. M. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. Obstet. Gynecol. 2002, 99 (1), 3-10.
23. Cuatrecasas, M.; Villanueva, A.; Matias-Guiu, X.; Prat, J. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 1997, 79 (8), 1581-1586.
24. McAlpine, J. N.; Wiegand, K. C.; Vang, R.; Ronnett, B. M.; Adamiak, A.; Kobel, M.; Kalloger, S. E.; Swenerton, K. D.; Huntsman, D. G.; Gilks, C. B.; Miller, D. M. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer 2009, 9, 433.
25. Dobrzycka, B.; Terlikowski, S. J.; Kinalski, M.; Kowalczuk, O.; Niklinska, W.; Chyczewski, L. Circulating free DNA and p53 antibodies in plasma of patients with ovarian epithelial cancers. Ann. Oncol. 2010, 22 (5), 1133-1140.
26. Hess, V.; A'Hern, R.; Nasiri, N.; King, D. M.; Blake, P. R.; Barton, D. P.; Shepherd, J. H.; Ind, T.; Bridges, J.; Harrington, K.; Kaye, S. B.; Gore, M. E. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J. Clin. Oncol. 2004, 22 (6), 1040-1044.
27. Pectasides, D.; Fountzilas, G.; Aravantinos, G.; Kalofonos, H. P.; Efstathiou, E.; Salamalekis, E.; Farmakis, D.; Skarlos, D.; Briasoulis, E.; Economopoulos, T.; Dimopoulos, M. A. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol. Oncol. 2005, 97 (2), 436-441.
28. Shimada, M.; Kigawa, J.; Ohishi, Y.; Yasuda, M.; Suzuki, M.; Hiura, M.; Nishimura, R.; Tabata, T.; Sugiyama, T.; Kaku, T. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol. Oncol. 2009, 113 (3), 331-334.
29. Pignata, S.; Ferrandina, G.; Scarfone, G.; Scollo, P.; Odicino, F.; Cormio, G.; Katsaros, D.; Villa, A.; Mereu, L.; Ghezzi, F.; Manzione, L.; Lauria, R.; Breda, E.; Alletti, D. G.; Ballardini, M.; Lombardi, A. V.; Sorio, R.; Mangili, G.; Priolo, D.; Magni, G.; Morabito, A. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer 2008, 8, 252.
30. Bamias, A.; Psaltopoulou, T.; Sotiropoulou, M.; Haidopoulos, D.; Lianos, E.; Bournakis, E.; Papadimitriou, C.; Rodolakis, A.; Vlahos, G.; Dimopoulos, M. A. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer 2010, 116 (6), 1462-1468.
31. Sato, S.; Itamochi, H.; Kigawa, J.; Oishi, T.; Shimada, M.; Sato, S.; Naniwa, J.; Uegaki, K.; Nonaka, M.; Terakawa, N. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci. 2009, 100 (3), 546-551.
32. Frumovitz, M.; Schmeler, K. M.; Malpica, A.; Sood, A. K.; Gershenson, D. M. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol. Oncol. 2010, 117 (3), 491-496.
33. Obata, K.; Morland, S. J.; Watson, R. H.; Hitchcock, A.; Chenevix-Trench, G.; Thomas, E. J.; Campbell, I. G. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res. 1998, 58 (10), 2095-2097.
34. Palacios, J.; Gamallo, C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res. 1998, 58 (7), 1344-1347.
35. Catasus, L.; Bussaglia, E.; Rodrguez, I.; Gallardo, A.; Pons, C.; Irving, J. A.; Prat, J. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum. Pathol. 2004, 35 (11), 1360-1368.
36. Gilks, C. B.; Ionescu, D. N.; Kalloger, S. E.; Kobel, M.; Irving, J.; Clarke, B.; Santos, J.; Le, N.; Moravan, V.; Swenerton, K. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum. Pathol. 2008, 39 (8), 1239-1251.
37. Kuo, K. T.; Mao, T. L.; Jones, S.; Veras, E.; Ayhan, A.; Wang, T. L.; Glas, R.; Slamon, D.; Velculescu, V. E.; Kuman, R. J.; Shih, I. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am. J. Pathol. 2009, 174 (5), 1597-1601.
38. Sugiyama, T.; Kamura, T.; Kigawa, J.; Terakawa, N.; Kikuchi, Y.; Kita, T.; Suzuki, M.; Sato, I.; Taguchi, K. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000, 88 (11), 2584-2589.
39. Crotzer, D. R.; Sun, C. C.; Coleman, R. L.; Wolf, J. K.; Levenback, C. F.; Gershenson, D. M. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol. Oncol. 2007, 105 (2), 404-408.
40. Goff, B. A.; Sainz de la, C. R.; Muntz, H. G.; Fleischhacker, D.; Ek, M.; Rice, L. W.; Nikrui, N.; Tamimi, H. K.; Cain, J. M.; Greer, B. E.; Fuller, A. F., Jr. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinumbased chemotherapy in stage III disease. Gynecol. Oncol. 1996, 60 (3), 412-417.
41. Pectasides, D.; Fountzilas, G.; Aravantinos, G.; Kalofonos, C.; Efstathiou, H.; Farmakis, D.; Skarlos, D.; Pavlidis, N.; Economopoulos, T.; Dimopoulos, M. A. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol. Oncol. 2006, 102 (2), 285-291.
42. Itamochi, H.; Kigawa, J.; Sugiyama, T.; Kikuchi, Y.; Suzuki, M.; Terakawa, N. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet. Gynecol. 2002, 100 (2), 281-287.
43. Takakura, S.; Takano, M.; Takahashi, F.; Saito, T.; Aoki, D.; Inaba, N.; Noda, K.; Sugiyama, T.; Ochiai, K. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int. J. Gynecol. Cancer 2010, 20 (2), 240-247.
44. Nagai, Y.; Inamine, M.; Hirakawa, M.; Kamiyama, K.; Ogawa, K.; Toita, T.; Murayama, S.; Aoki, Y. Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary. Gynecol. Oncol. 2007, 107 (3), 469-473.
45. Miyazawa, M.; Yasuda, M.; Fujita, M.; Kajiwara, H.; Hirabayashi, K.; Takekoshi, S.; Hirasawa, T.; Murakami, M.; Ogane, N.; Kiguchi, K.; Ishiwata, I.; Mikami, M.; Osamura, R. Y. Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol. Int. 2009, 59 (1), 19-27.
46. Kobayashi, H.; Kajiwara, H.; Kanayama, S.; Yamada, Y.; Furukawa, N.; Noguchi, T.; Haruta, S.; Yoshida, S.; Sakata, M.; Sado, T.; Oi, H. Molecular pathogenesis of endometriosisassociated clear cell carcinoma of the ovary (review). Oncol. Rep. 2009, 22 (2), 233-240.
47. Zorn, K. K.; Bonome, T.; Gangi, L.; Chandramouli, G. V.; Awtrey, C. S.; Gardner, G. J.; Barrett, J. C.; Boyd, J.; Birrer, M. J. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin. Cancer Res. 2005, 11 (18), 6422-6430.
48. Stany, M. P.; Vathipadiekal, V.; Ozbun, L.; Stone, R. L.; Mok, S. C.; Xue, H.; Kagami, T.; Wang, Y.; McAlpine, J. N.; Bowtell, D.; Gout, P. W.; Miller, D. M.; Gilks, C. B.; Huntsman, D. G.; Ellard, S. L.; Wang, Y. Z.; Vivas-Mejia, P.; Lopez-Berestein, G.; Sood, A. K.; Birrer, M. J. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One 2011, 6 (7), e21121.
49. Rauh-Hain, J. A.; Penson, R. T. Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. Int. J. Gynecol. Cancer 2008, 18 (5), 934-936.
50. Anglesio, M. S.; George, J.; Kulbe, H.; Friedlander, M.; Rischin, D.; Lemech, C.; Power, J.; Coward, J.; Cowin, P. A.; House, C. M.; Chakravarty, P.; Gorringe, K. L.; Campbell, I. G.; Okamoto, A.; Birrer, M. J.; Huntsman, D. G.; de, F. A.; Kalloger, S. E.; Balkwill, F.; Gilks, C. B.; Bowtell, D. D. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin. Cancer Res. 2011, 17 (8), 2538-2548.
51. Matsumura, N.; Mandai, M.; Okamoto, T.; Yamaguchi, K.; Yamamura, S.; Oura, T.; Baba, T.; Hamanishi, J.; Kang, H. S.; Matsui, S.; Mori, S.; Murphy, S. K.; Konishi, I. Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Sci. 2010, 101 (12), 2658-2663.
52. Hogdall, E. V.; Christensen, L.; Hogdall, C. K.; Blaakaer, J.; Gayther, S.; Jacobs, I. J.; Christensen, I. J.; Kjaer, S. K. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol. Rep. 2007, 18 (5), 1051-1059.
53. Tangjitgamol, S.; Manusirivithaya, S.; Khunnarong, J.; Jesadapatarakul, S.; Tanwanich, S. Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study. Int. J. Gynecol. Cancer 2009, 19 (4), 620-627.
54. Wong, K. K.; Lu, K. H.; Malpica, A.; Bodurka, D. C.; Shvartsman, H. S.; Schmandt, R. E.; Thornton, A. D.; Deavers, M. T.; Silva, E. G.; Gershenson, D. M. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int. J. Gynecol. Pathol. 2007, 26 (4), 404-409.
55. Rao, G. G.; Miller, D. S. Hormonal therapy in epithelial ovarian cancer. Expert. Rev. Anticancer Ther. 2006, 6 (1), 43-47.
56. Emons, G.; Ortmann, O.; Teichert, H. M.; Fassl, H.; Lohrs, U.; Kullander, S.; Kauppila, A.; Ayalon, D.; Schally, A.; Oberheuser, F. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma. A prospective double blind randomized trial. Decapeptyl Ovarian Cancer Study Group. Cancer 1996, 78 (7), 1452-1460.
57. du Bois, A.; Meier, W.; Luck, H. J.; Emon, G.; Moebus, V.; Schroeder, W.; Costa, S.; Bauknecht, T.; Olbricht, S.; Jackisch, C.; Richter, B.; Wagner, U. Chemotherapy versus hormonal treatment in platinum and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann. Oncol. 2002, 13 (2), 251-257.
58. Williams, C.; Simera, I.; Bryant, A. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst. Rev. 2010, 17 (3), CD001034.
59. Hurteau, J. A.; Brady, M. F.; Darcy, K. M.; McGuire, W. P.; Edmonds, P.; Pearl, M. L.; Ivanov, I.; Tewari, K. S.; Mannel, R. S.; Zanotti, K.; Benbrook, D. M. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemicalrecurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol. Oncol. 2010, 119 (3), 444-450.
60. Smyth, J. F.; Gourley, C.; Walker, G.; Mackean, M. J.; Stevenson, A.; Williams, A. R.; Nafussi, A. A.; Rye, T.; Rye, R.; Stewart, M.; McCurdy, J.; Mano, M.; Reed, N.; McMahon, T.; Vasey, P.; Gabra, H.; Langdon, S. P. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptorpositive patients. Clin. Cancer Res. 2007, 13 (12), 3617-3622.
61. Argenta, P. A.; Thomas, S. G.; Judson, P. L.; Downs, L. S. Jr.; Geller, M. A.; Carson, L. F.; Jonson, A. L.; Ghebre, R. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol. Oncol. 2009, 113 (2), 205-209.
62. Nagy, A.; Schally, A. V. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol. Reprod. 2005, 73 (5), 851-859.
63. Kobel, M.; Reuss, A.; Bois, A.; Kommoss, S.; Kommoss, F.; Gao, D.; Kalloger, S. E.; Huntsman, D. G.; Gilks, C. B. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J. Pathol. 2010, 222 (2), 191-198.
64. Ahmed, A. A.; Etemadmoghadam, D.; Temple, J.; Lynch, A. G.; Riad, M.; Sharma, R.; Stewart, C.; Fereday, S.; Caldas, C.; Defazio, A.; Bowtell, D.; Brenton, J. D. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 2010, 221 (1), 49-56.
65. Leijen, S.; Beijnen, J. H.; Schellens, J. H. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr. Clin. Pharmacol. 2010, 5 (3), 186-191.
66. Lambeck, A.; Leffers, N.; Hoogeboom, B. N.; Sluiter, W.; Hamming, I.; Klip, H.; ten, H. K.; Esajas, M.; van, O. M.; Drijfhout, J. W.; Platteel, I.; Offringa, R.; Hollema, H.; Melief, K.; van der, B. S.; van der, Z. A.; Daemen, T.; Nijman, H. P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy. Int. J. Cancer 2007, 121 (3), 606-614.
67. Leffers, N.; Lambeck, A. J.; Gooden, M. J.; Hoogeboom, B. N.; Wolf, R.; Hamming, I. E.; Hepkema, B. G.; Willemse, P. H.; Molmans, B. H.; Hollema, H.; Drijfhout, J. W.; Sluiter, W. J.; Valentijn, A. R.; Fathers, L. M.; Oostendorp, J.; van der Zee, A. G.; Melief, C. J.; van der Burg, S. H.; Daemen, T.; Nijman, H. W. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int. J. Cancer 2009, 125 (9), 2104-2113.
68. Kwon, J. S.; Daniels, M. S.; Sun, C. C.; Lu, K. H. Preventing future cancers by testing women with ovarian cancer for BRCA mutations. J. Clin. Oncol. 2010, 28 (4), 675-682.
69. Alsop, K.; Fereday, S.; Meldrum, C.; Defazio, A.; Emmanuel, C.; George, J.; Dobrovic, A.; Birrer, M. J.; Webb, P. M.; Stewart, C.; Friedlander, M.; Fox, S.; Bowtell, D.; Mitchell, G. BRCA mutation frequency and patterns of treatment response in BRCA mutationpositive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J. Clin. Oncol. 2012, 30 (21), 2654-2663.
70. Baldwin, R. L.; Nemeth, E.; Tran, H.; Shvartsman, H.; Cass, I.; Narod, S.; Karlan, B. Y. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 2000, 60 (19), 5329-5333.
71. Ashworth, A. A synthetic lethal therapeutic approach: poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 2008, 26 (22), 3785-3790.
72. Schreiber, V.; Dantzer, F.; Ame, J. C.; de, M. G. Poly (ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 2006, 7 (7), 517-528.
73. Schultz, N.; Lopez, E.; Saleh-Gohari, N.; Helleday, T. Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res. 2003, 31 (17), 4959-4964.
74. Iglehart, J. D.; Silver, D. P. Synthetic lethality--a new direction in cancer-drug development. N. Engl. J. Med. 2009, 361 (2), 189-191.
75. Fong, P. C.; Boss, D. S.; Yap, T. A.; Tutt, A.; Wu, P.; Mergui-Roelvink, M.; Mortimer, P.; Swaisland, H.; Lau, A.; O'Connor, M. J.; Ashworth, A.; Carmichael, J.; Kaye, S. B.; Schellens, J. H.; de Bono, J. S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009, 361 (2), 123-134.
76. Audeh, M. W.; Carmichael, J.; Penson, R. T.; Friedlander, M.; Powell, B.; Bell-McGuinn, K. M.; Scott, C.; Weitzel, J. N.; Oaknin, A.; Loman, N.; Lu, K.; Schmutzler, R. K.; Matulonis, U.; Wickens, M.; Tutt, A. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376 (9737), 245-251.
77. Gelmon, K. A.; Tischkowitz, M.; Mackay, H.; Swenerton, K.; Robidoux, A.; Tonkin, K.; Hirte, H.; Huntsman, D.; Clemons, M.; Gilks, B.; Yerushalmi, R.; Macpherson, E.; Carmichael, J.; Oza, A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011, 12 (9), 852-861.
78. Birrer, M. J.; Konstantinopoulos, P.; Penson, R. T.; Roche, M.; Ambrosio, A.; Stallings, T. E.; Matulonis, U.; Bradley, C. R. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer. J. Clin. Oncol. 2011, 29 (15S).
79. Dean, E.; Middleton, M. R.; Pwint, T.; Swaisland, H.; Carmichael, J.; Goodege-Kunwar, P.; Ranson, M. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br. J. Cancer 2012, 106 (3), 468-474.
80. Meindl, A.; Hellebrand, H.; Wiek, C.; Erven, V.; Wappenschmidt, B.; Niederacher, D.; Freund, M.; Lichtner, P.; Hartmann, L.; Schaal, H.; Ramser, J.; Honisch, E.; Kubisch, C.; Wichmann, H. E.; Kast, K.; Deissler, H.; Engel, C.; Muller-Myhsok, B.; Neveling, K.; Kiechle, M.; Mathew, C. G.; Schindler, D.; Schmutzler, R. K.; Hanenberg, H. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat. Genet. 2010, 42 (5), 410-414.
81. Farley, J.; Brady, W.; Birrer, M.; Lankes, H.; Coleman, R.; Morgan, M.; Mannel, R.; Yamada, D.; Mutch, D.; Gershenson, D. A phase II trial of AZD6244 in women with recurrent low-grade serous carcinoma of the ovary or peritoneum. Int. J. Gynaecol. Cancer 2011, 21 (suppl 3), 38.
82. Yamamoto, S.; Tsuda, H.; Miyai, K.; Takano, M.; Tamai, S.; Matsubara, O. Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas. Mod. Pathol. 2012, 25 (1), 122-130.
83. Yamamoto, S.; Tsuda, H.; Miyai, K.; Takano, M.; Tamai, S.; Matsubara, O. Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. Mod. Pathol. 2011, 24 (8), 1146-1155.
84. Yakes, F. M.; Chen, J.; Tan, J.; Yamaguchi, K.; Shi, Y.; Yu, P.; Qian, F.; Chu, F.; Bentzien, F.; Cancilla, B.; Orf, J.; You, A.; Laird, A. D.; Engst, S.; Lee, L.; Lesch, J.; Chou, Y. C.; Joly, A. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol. Cancer. Ther. 2011, 10 (12), 2298-2308.
85. Lalwani, N.; Prasad, S. R.; Vikram, R.; Shanbhogue, A. K.; Huettner, P. C.; Fasih, N. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. Radiographics 2011, 31 (3), 625-646.
86. Angelsio, M. S.; Kommoss, S.; Tolcher, M. C.; Clarke, B.; Galletta, L.; Porter, H.; Damaraju, S.; Fereday, S.; Winterhoff, B. J.; Kalloger, S. E.; Senz, J.; Yang, W.; Steed, H.; Allo, G.; Ferguson, S.; Shaw, P.; Teoman, A.; Garcia, J. J.; Schoolmeester, J. K.; Bakkum-Gamez, J.; Tinker, A. V.; Bowtell, D. D.; Huntsman, D. G.; Gilks, C. B.; McAlpine, J. N. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J. Pathol. 2013, 229 (1), 111-120.